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Abstract
Intra-arterial transplantation of mesoangioblasts proved safe and
partially efficacious in preclinical models of muscular dystrophy.
We now report the first-in-human, exploratory, non-randomized
open-label phase I–IIa clinical trial of intra-arterial HLA-matched
donor cell transplantation in 5 Duchenne patients. We administered
escalating doses of donor-derived mesoangioblasts in limb arteries
under immunosuppressive therapy (tacrolimus). Four consecutive
infusions were performed at 2-month intervals, preceded and
followed by clinical, laboratory, and muscular MRI analyses.
Two months after the last infusion, a muscle biopsy was performed.
Safety was the primary endpoint. The study was relatively safe: One
patient developed a thalamic stroke with no clinical consequences
and whose correlation with mesoangioblast infusion remained
unclear. MRI documented the progression of the disease in 4/5
patients. Functional measures were transiently stabilized in 2/3
ambulant patients, but no functional improvements were observed.
Low level of donor DNA was detected in muscle biopsies of 4/5
patients and donor-derived dystrophin in 1. Intra-arterial transplan-
tation of donor mesoangioblasts in human proved to be feasible and
relatively safe. Future implementation of the protocol, together with
a younger age of patients, will be needed to approach efficacy.
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Introduction
Duchenne muscular dystrophy (DMD) is the most common muscu-
lar dystrophy, due to mutations of the X-linked dystrophin gene
(Hoffman et al, 1987; Mercuri & Muntoni, 2013a). It causes a
progressive degeneration of skeletal and cardiac muscle, leading the
patient to reduced motility, wheelchair confinement, and early
death, usually due to cardiac and/or respiratory failure (Muntoni
et al, 2003; Davies & Nowak, 2006). Drug and physical therapy have
extended patients’ life span but only modestly its quality (Manzur
et al, 2008; Manzur & Muntoni, 2009).
A number of new therapies for DMD have entered clinical devel-
opment, and some have progressed to phase III (Benedetti et al,
2013; Leung & Wagner, 2013; Mercuri & Muntoni, 2013b; Ruegg,
2013; Bushby et al, 2014; Leung et al, 2014; Seto et al, 2014; Voit
et al, 2014; Witting et al, 2014; Buyse et al, 2015). All appear to be
safe but are often limited to a subset of patients, and long-lasting
efficacy has still to be reached.
In the past, we have characterized mesoangioblasts (MABs), a
subset of pericytes, from mouse, dog, and human skeletal muscle
that can be expanded in culture and maintain the ability to differen-
tiate into skeletal and smooth muscle (Minasi et al, 2002; Dellavalle
et al, 2007, 2011). Noteworthy, MABs are able to cross the vessel
wall when delivered intra-arterially and can thus be distributed to
downstream tissues, provided that inflammation and consequent
activation of the endothelium are present, as in disease progression
of DMD. We tested a protocol of cell therapy in four murine and
one canine model of muscular dystrophies, demonstrating safety
and partial efficacy of this approach (Sampaolesi et al, 2003, 2006;
Diaz-Manera et al, 2010; Tedesco et al, 2011, 2012; Domi et al,
2015).
Following an observational study in 28 DMD patients (Pts) aimed
at defining longitudinally the disease progression (Lerario et al,
2012), five were enrolled to a “first-in-human” phase I/IIa trial of
HLA-matched sibling donor MABs under immunosuppression
(Eudract 2011-000176-33).
Results
Intra-arterial mesoangioblast infusions
Five patients (details in Table 1) underwent transplantation of
MABs obtained from a muscle biopsy of an HLA-matched
brother. Target dose of MABs was consistent with doses adminis-
tered to dystrophic dogs in preclinical tests (Sampaolesi et al,
2006). All patients received at least four infusions (Appendix Fig
S1) in upper and lower (Pt 01, Pt 02, Pt 03) or only lower limbs
(Pt 05, Pt 06), under immunosuppression regimen (tacrolimus).
The cells used as MP underwent a number of controls before
infusion and showed the features reported in Appendix Table S1.
In essence, they were still able of good proliferation, expressed
the expected phenotype (Tonlorenzi et al, 2007), and had vari-
able ability to differentiate into multinucleated myotubes in
culture.
MAB infusions were in general well tolerated; however, one
SAE, a thalamic stroke in Pt 03, was observed out of 23 infusions
(see below and Appendix Table S2 for details).
In Pt 01 and Pt 03, cell dose was inferior to target. Immediately
after MAB infusion, an asymptomatic cutaneous reticulum (livedo
reticularis) appeared in the left abdominal lower quadrant (Fig 1A)
in Pt 01 and disappeared spontaneously after 1 day; it was attrib-
uted to the infusion of small cell clumps, occasionally appearing in
confluent cultures (Fig 1B). Also, Pt 02 showed a transient livedo
reticularis after two MAB infusions (in left hand and left limb;
Fig 1C). More details and a comparison with healthy children of the
same age are reported in the legend to Appendix Table S2. To avoid
the occurrence of cell clumps, we amended the protocol to allow fil-
tration of the MP with a 70-lm cell strainer.
In Pt 03, during the first MAB infusion, the pre-infusion diagnos-
tic angiography of the right lower limb revealed contrast inflow
delay, likely due to vasospasm of the ipsilateral iliac–femoral arte-
rial axis. The patient was thus infused on the contralateral patent
artery after iliac crossing; the vasospasm resolved after injection of
vasodilator. Pt 03 showed one SAE after the fourth (last) infusion.
Five hours after MAB infusion, the Pt had an episode of vomiting
and atrial fibrillation was revealed (but we do not know when it
started since the Pt had not been monitored after the infusion),
which resolved spontaneously one hour after having being detected.
ECG, echocardiography, and color Doppler ultrasound of arteries at
four limbs were all normal. The subsequent night, he had headache,
photophobia, and vomiting, which solved with paracetamol. Neuro-
logical examination was normal, but brain MRI showed an acute
thalamic stroke (Fig 1D). Intracranial arterial and venous MR
angiography (MRA) and contrast-enhanced MRA of the supra-aortic
arteries showed normal caliber and flow signal of the examined
vessels. Transcranial Doppler ultrasound with micro-bubbles was
normal. He was started on oral aspirin and no further complication
occurred. Cerebral MRI 1 month later showed normal evolution of
the ischemic lesion (Fig 1E). No new lesions or any clinical conse-
quences were detected.
Due to the stroke in Pt 03, study Data Safety Monitoring Board
(DSMB) recommended in Pt 05 and Pt 06 MAB infusions only in
lower limbs for safety and with the intention to increase cell dose to
reach target treatment in lower limbs. No SAEs were observed in
these last patients (10 infusions).
Donor cell engraftment and dystrophin expression
Muscle biopsies performed 2 months after the last infusion showed
histological features of muscular dystrophy in all patients (Fig 2A
and B). Fiber regeneration (identified by anti-fetal myosin) was
minimal, ranging from 3 to 32% (Fig 2C), and rather low as
compared to those usually observed in younger DMD patients
(50–60%). The DNA chimerism analysis revealed minimal donor
cell engraftment, ranging from 0.00 to 0.69% (Appendix Table S3).
Pt 01 and Pt 03 showed virtually no dystrophin expression by
immunohistochemistry (Fig 3A). Pt 02 showed scattered, faint,
dystrophin positivity in some muscle fibers in post-treatment biop-
sies. Fiber staining was discontinuous, but revealed also with anti-
dys1 antibody, which recognizes a portion of deleted protein absent
in revertant fibers (Fig 3B). Pt 05 and Pt 06 showed some fibers
positive for dystrophin in both pre- and post-treatment samples
(Fig 3C and D). We then applied semi-quantitative measurement of
dystrophin expression levels comparing pre-treatment muscle of Pt
01 (sample of muscle obtained from the biopsy performed at time of
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Figure 1. Side effects of MAB treatment of DMD patients.
A Livedo reticularis in the left abdominal lower quadrant after the first infusion in Pt 01.
B Small clump of MABs observed in the first preparation of MP before the infusion of Pt 01. Scale bar, 30 lm.
C Livedo reticularis in the left hand of Pt 02 after the first infusion.
D Brain MRI acquired 1 day after the MAB infusion showing acute small thalamic stroke in Pt 03. Axial diffusion-weighted imaging (left) and fluid-attenuated inversion
recovery (FLAIR; right) images show a focal spot of hyperintensity within the right thalamus consistent with acute stroke.
E FLAIR MRI axial image obtained in Pt 03 1 month after the acute stroke, showing the expected evolution of the right thalamic lesion.
Table 1. Patient clinical features.
Pt 01 Pt 02 Pt 03 Pt 05 Pt 06
Dystrophin mutations Exon deletion
47–52
Exon deletion
4–44
Exon deletion
45–50
Point mutation
Exon 43
Point mutation
Exon 59
Steroid (mg/kg) Deflazacort 0.75/every
other day
Deflazacort 0.7/every
other day
Prednisone
0.5/daily
Deflazacort 0.9/every
other day
Deflazacort 0.5/every
other day
Age at first infusion (year) 12.4 8.5 9.6 9.2 12.2
Loss of ambulation (age) 12 10.2 10.8 Preserved walk ability 12.1
Weight (kg)a 50 25 37 38 46
Height (cm)a 137 123 140 126 160
Cardiac function Normal Normal Normal Normal Normal
Lung function Normal Normal Normal Normal Normal
Other comorbidities None None None None None
aMeasured at first infusion.
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diagnosis), Pt 05 and Pt 06 (muscle biopsy performed before MAB
therapy) with levels in post-treatment muscle. Pt 05 showed modest
post-treatment increase of dystrophin levels with anti-dys2 anti-
body, as mean dystrophin fluorescence intensity increased from 3 to
11% of normal control after treatment. Pt 01 and Pt 06 did not show
any increase in protein expression (Appendix Fig S2). However,
similar quantification with anti-dys1 antibody did not show any
increase in dystrophin levels in Pt 01 and Pt 05, whereas a modest
increase was observed in Pt 06 (from 11 to 22%; Appendix Fig S2).
Western blot analysis did not show any band corresponding to
full-length dystrophin (427 kD) in Pt 01 (Fig 3E) and Pt 03 (data not
shown). Pt 02 did not show full-length dystrophin in pre-treatment
sample, whereas a faint band corresponding to full-length dystro-
phin was observed with anti-mandys18 and manex46e antibodies
only in post-treatment samples (Fig 3F). Interestingly, mandys18
recognizes peptides from exons 17–35, deleted in Pt 02 (deletion
4–44), thus not present in revertant fibers. Pt 05 and Pt 06 (point
mutations) showed bands corresponding to dystrophin in both pre-
and post-treatment samples, detected only after protein concentra-
tion with Amicon Ultra-0.5 centrifugal filter devices (Millipore)
(Fig 3G and H). The amount of protein did not differ in pre- to post-
treatment sample in Pt 06, whereas it was increased in post-
treatment sample in Pt 05 (Fig 2G). Since Pt 02 has a deletion of 40
exons, the faint band of full molecular weight detected by Western
blot may only derive from donor (MAB) cells. In the case of Pt 05
and Pt 06, the presence of a point mutation makes it impossible to
distinguish between donor and revertant dystrophin by Western blot
analysis. For this reason, we conducted Sanger sequencing of Pt 05
muscle cDNA, which only detected mutated cDNA (Appendix Fig
S3). To increase sensitivity, we performed next-generation sequenc-
ing and a tetraprimer PCR assay (Appendix Fig S3) to detect the
polymorphism. However, also these sensitive methods failed to
detect donor cDNA but also ruled out skipping of the mutated allele,
which was still present as the totality of the sample.
◀ Figure 2. Muscle biopsies of DMD-treated patients.A Hematoxylin and eosin staining of muscle biopsies from Pt 01, Pt 02, and Pt 03 performed 2 months after the last MAB infusion. Images show diffuse increase of
connective tissue, atrophic and hypertrophic fibers, degenerating fibers, and diffuse centralization of nuclei. Scale bar, 100 lm.
B Hematoxylin and eosin staining of muscle biopsies from Pt 05 and Pt 06 performed 1 month before the first MAB infusion and 2 months after the last MAB infusion.
Images show diffuse increase of connective tissue, atrophic and hypertrophic fibers, degenerating fibers, and diffuse centralization of nuclei. No evident differences
were observed between biopsy performed after and before treatment. Scale bar, 100 lm.
C Immunohistochemistry showing fetal myosin expression in muscle biopsy of DMD patients performed 2 months after the last MAB infusion. The staining was
performed in tibialis anterior muscle for Pt 01, Pt 02, and Pt 03 and in gastrocnemius muscle for Pt 05 and Pt 06. A higher number of positive (brownish staining)
fibers (representing regenerating fibers) were observed in Pt 02, Pt 05, and Pt 06. Scale bar, 100 lm.
Figure 3. Effects of MAB treatment on dystrophin expression.
A Confocal immunofluorescence of muscle biopsy from Pt 01 (tibialis anterior post-treatment) stained with anti-dystrophin dys1 antibody (which recognizes protein
fragment encoded by exons 26–30, green signal) and anti-laminin-2 (to delineate muscle fibers, red signal); DAPI identifies nuclei (blue signal). In the left image, only
anti-dystrophin staining is shown. No dystrophin-positive fibers were observed. Scale bar, 100 lm.
B Confocal immunofluorescence of muscle biopsy from Pt 02 (tibialis anterior post-treatment) stained with anti-dystrophin dys1 antibody (green signal) and anti-
laminin-2 (red signal); DAPI identifies nuclei (blue signal). In the left image, only anti-dystrophin staining is shown. Some fiber shows mild and discontinuous
dystrophin staining. Scale bar, 100 lm.
C Immunofluorescence of muscle biopsy from Pt 05 taken before (left, gastrocnemius) and after treatment (right, gastrocnemius) stained with anti-dystrophin dys2
antibody (which recognizes exons 77–79). The number and intensity of dystrophin-positive fibers is increased in the post-treatment biopsy. Scale bar, 80 lm.
D Immunofluorescence of muscle biopsy from Pt 06 taken before (left, gastrocnemius) and after treatment (right, gastrocnemius) stained with anti-dystrophin dys2
antibody. Few fibers show scattered dystrophin staining, without obvious differences between pre- and post-treatment samples. Scale bar, 80 lm.
E Results of Western blot analysis involving dystrophin antibodies dys1, Mandys18, and Manex46e (recognizing respectively exons 26–30, 17–35, and 46), of total
protein extracts (20 lg) obtained from post-treatment biopsy specimens of Pt 01 (tibialis anterior muscle); Ct was used as a positive dystrophin control. Below, bands
corresponding to myosin heavy chain are shown as a loading control. No bands corresponding to full-length dystrophin were observed. A schematic representation of
the deleted portion of the dystrophin and the region recognized by the used antibodies is depicted above the Western blot.
F Results of Western blot analysis, involving dystrophin antibodies Mandys18 and Manex46e, of total protein extracts (10–20 lg) obtained from pre-treatment
(performed at time of diagnosis) and post-treatment biopsy specimens of Pt 02 (tibialis anterior muscle); Ct was used as a positive dystrophin control, CtDmd was
used as a dystrophin-negative control. Below, bands corresponding to myosin heavy chain are shown as a loading control. One faint band corresponding to
full-length dystrophin is observed only in the post-treatment samples with both Mandys18 and Manex46e antibodies. A schematic representation of the deleted
portion of the dystrophin and the region recognized by used antibodies is depicted above the Western blot.
G Results of Western blot analysis, involving dystrophin antibodies Mandys106 (recognizing exon 43) and dys1, of total protein extracts (80 lg, following protein
concentration by Amicon Ultra-0.5 centrifugal filter devices; Millipore) obtained from pre-treatment and post-treatment biopsy specimens of Pt 05 (gastrocnemius);
Ct was used as a positive dystrophin control. Below, bands corresponding to myosin heavy chain are shown as a loading control. Bands corresponding approximately
to full-length dystrophin are observed in pre- and post-treatment samples with both antibodies. However, bands in post-treatment sample appeared higher in
amount. A schematic representation of the dystrophin point mutation (black vertical bar) and the region recognized by the used antibodies is depicted above the
Western blot.
H Results of Western blot analysis, involving dystrophin antibodies Mandys106 and dys1, of total protein extracts (80 lg, following protein concentration by Amicon
Ultra-0.5 centrifugal filter devices, Millipore) obtained from pre-treatment and post-treatment biopsy specimens of Pt 06 (gastrocnemius); Ct was used as a positive
dystrophin control. Below, bands corresponding to myosin heavy chain are shown as a loading control. Bands corresponding approximately to full-length dystrophin
are observed in pre- and post-treatment samples with both antibodies. Bands in pre-treatment sample appeared higher in amount as compared to post-treatment
sample. A schematic representation of the dystrophin point mutation (black vertical bar) and the region recognized by the used antibodies is depicted above the
Western blot.
Source data are available online for this figure.
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MRI of the lower limbs
In all MRI examinations, no signs of ischemic muscle damage,
abnormal muscle edema, or ectopic/expansive lesions were
detected. Signal intensity ratio (SIR) and muscle segmental
volumes indexes (MVIs) obtained from the post-processing analy-
ses of hip and lower limb muscles of transplanted patients were
compared to those obtained with 85 MRI acquisitions performed
on 26 untreated DMD patients who underwent a natural history
study (Lerario et al, 2012). Four to five pre-treatment MRI exami-
nations were available also for DMD transplanted patients (Fig 4
and Appendix Fig S4). In Pt 05, a significant post-transplant
amelioration of the trend of MRI parameters was observed for SIRs
of all analyzed thigh muscles (quadriceps, thigh flexor muscles,
gracilis, sartorius) and for MVIs of quadriceps and semitendinosus
(Fig 4); MVIs of soleus, biceps, and gracilis muscles did not reach
a significant modification of the trend though a detectable improve-
ment was observed. After treatment in Pt 06, SIRs and MVI
remained relatively stable and above the 95th percentile of the
disease natural history cohort (Fig 4B and Appendix Fig S4), but
no significant modification of the trend was detected. No improve-
ment was observed in Pt 01, Pt 02, and Pt 03.
Clinical progression of the disease
All patients complied well with MAB infusions schedule and
performed all planned functional and clinical tests. Respiratory and
cardiac functions remained stable in all patients throughout the
period of transplantation (Table 1). Pt 01 and Pt 06 were already
wheelchair bound, and their motility could not be analyzed by func-
tional tests. Pt 02 and Pt 03, although ambulant, could not perform
Gowers’ test already before infusions. Pt 02, who was undergoing a
rapid deterioration of motor functions, appeared to stabilize, follow-
ing cell infusions from April 2011 to August 2012, when he grew in
height and weight, begun to limp and fall spontaneously, and within
5 months became wheelchair bound. Pt 03 progressively worsened
in his quantitative and functional measures despite MAB infusions
and in December 2011 lost ambulation. Finally, Pt 05 who was
stable at the onset of the infusions (November 2012) remained
stable until the end of 2014, when his performance worsened, possi-
bly due to spontaneous stop of steroid (reintroduced in April 2015;
Fig 5 and Appendix Fig S5). Quantitative measures with Kin-Com
ergometer did not show significant changes after cell infusions in all
the patients except for Pt 05. This patient showed an attenuated
decrease in all the Kin-Com parameters after the infusions, as
compared with his own previous slope before age 7.5 years
(Appendix Fig S6). Creatine kinase levels did not show any
dose–infusion correlation in all five patients. Based on these results,
immunosuppression with tacrolimus was gradually tapered and
discontinued in all but Pt 05.
Immunological studies
To evaluate the immunological effects of tacrolimus administration
and multiple MAB infusions from HLA-matched siblings, immuno-
logical responses were analyzed every 2 months. Lymphocytes
counts and the relative distribution of T-cell differentiation subsets
remained stable and within the normal ranges throughout the study
(Appendix Fig S7A–F). Importantly, in CMV- and EBV-seropositive
patients, high frequencies of CMV-specific (average 103 spot-
forming cells (sfc)) and EBV-specific (average 193 sfc) T-cell
responses were detected by IFN-c ELISpot throughout the study
(Fig 6A), indicating that this dose of tacrolimus does not affect
memory T-cell responses (Egli et al, 2013). Accordingly, infectious
serious adverse events were not recorded.
We next investigated the development of alloreactive immune
responses that could be elicited by allogeneic donor cell infusions
(Noviello et al, 2014). MABs, MABs activated by IFN-c (cMAB),
myotubes differentiated from MABs, and PBMC harvested from each
MAB donor were used as stimulators (Fig 6A). After treatment, Pt
01 showed a weak response to MAB (average 37 sfc), cMAB (aver-
age 32 sfc), and myotubes (average 18 sfc). Similarly, in Pt 06, a
weak expansion of the T-cell response to cMAB was observed (aver-
age 26 sfc). In contrast, in Pt 02 and Pt 05 we did not detect alloreac-
tive responses at any time point. Only Pt 03 showed a high basal
alloreactive response before treatment: 34 sfc against MAB, 25 sfc
against cMAB, and 77 sfc against myotubes. These responses rose
up after treatment, and the reaction toward myotubes (158 sfc)
exceeded EBV-specific response (118 sfc) at 6 m. It is noteworthy
that, after in vitro stimulation, PBMC from Pt 03 recognized and
killed donor cells, including myotubes (Appendix Fig S7H). Thus,
alloreactive responses were undetectable in Pt 02 and Pt 05, while a
strong response was observed in Pt 03 and week responses in Pt 01
and Pt 06.
Nearly 20% of DMD patients under steroid treatment are likely
to present a specific T-cell response to dystrophin (Flanigan et al,
2013). Thus, we evaluated putative T-cell responses to a library of
overlapping peptides covering a large portion of the dystrophin
protein sequence (Fig 6B). PBMC harvested from Pt 01, Pt 02, Pt 03,
and Pt 05 did not recognize dystrophin peptide pools. Pt 06 showed
weak activation after challenging with pool 5, both before (16 sfc)
and after treatment (14 sfc), suggesting that the dystrophin-specific
Figure 4. Effects of MAB treatment on MRI of lower limbs.
A Axial T1-weighted images of the right thighs obtained in patients immediately before (upper panel) and 18 months after MAB infusion. Please note the progression of
fatty degeneration and atrophy except for Pt 05 where no evident modifications can be detected.
B Representative percentile of MRI quantitative parameters in transplanted patients compared to untreated patients. SIR (left image) and MVI (right image) of the
quadriceps. Red line: Pt 01; dotted green line: Pt 02; dotted purple line: Pt 03; dotted dark blue line: Pt 05; dotted light blue line: Pt 06). Empty dots correspond to pre-
treatment measures. Orange dots correspond to post-transplantation measurement. The black line corresponds to the median, while gray dotted lines to 75th, 90th,
and 95th percentile. Please note the modification of the trend of Pt 05 after treatment.
C Representative quantile spline regressions of post-transplant trend amelioration of MRI quantitative parameters in Pt 05. Upper left: SIR of the quadriceps. Lower left:
SIR of thigh flexor muscles. Upper right: MVI of the quadriceps. Lower right: MVI of the semitendinosus muscles. Please note the significant modification of the
patient trend (red lines) compared to median measurements obtained with 85 MRI examinations of untreated patients. Empty dots correspond to pre-treatment
measures. Full dots correspond to post-transplantation measurement. The gray dotted line corresponds to the time of the first intra-arterial transplantation.
▸
ª 2015 The Authors EMBO Molecular Medicine Vol 7 | No 12 | 2015
Giulio Cossu et al Mesoangioblast cell therapy in Duchenne EMBO Molecular Medicine
1519
Published online: November 5, 2015 
AB
C
Figure 4.
EMBO Molecular Medicine Vol 7 | No 12 | 2015 ª 2015 The Authors
EMBO Molecular Medicine Mesoangioblast cell therapy in Duchenne Giulio Cossu et al
1520
Published online: November 5, 2015 
immunity observed was not boosted by MAB infusions. Proteins
extracted from a healthy donor muscle biopsy were incubated with
patients’ and healthy donors’ sera to evaluate humoral responses to
dystrophin. No circulating antibodies to dystrophin were detected
(Appendix Fig S7G).
Discussion
We report the results of a proof-of-concept phase I/IIa trial consist-
ing multiple intra-arterial infusions of HLA-matched donor MABs in
five DMD patients.
We first demonstrated the feasibility of a large-scale production
under GMP conditions of MABs from a related donor of DMD
patients, in fractionated doses according to a schedule of repeated
therapeutic infusions. We also demonstrated that it is clinically
feasible and relatively safe to inject hundreds of millions of non-
hematopoietic stem cells into the peripheral arterial circulation of
pediatric patients, a procedure never reported previously. This by
itself has major implications for a number of different trials:
Currently, there are approximately 400 clinical trials, mostly based
upon intravenous administration of allogeneic or autologous
mesenchymal stem cells (MSC) for a variety of disorders (Sharma
et al, 2014). However, the vast majority of injected cells will be
trapped in the lung (Schrepfer et al, 2007), as the first capillary
filter, whereas an intra-arterial administration of these cells
may direct them to the specific anatomical district favoring their
engraftment and eventual function.
One SAE out of 23 infusions (4.3%), a thalamic stroke, occurred
in Pt 03 after the last infusion. The cause of the thalamic stroke
remains unclear; however, this event has been reported to occur
spontaneously in approximately 1% of DMD patients (Hanajima &
Kawai, 1996). We excluded artery dissection and embolism from
patent foramen ovale. Stroke may have been caused by a cardio-
embolic event during atrial fibrillation, the most common mecha-
nism of cerebral infarction described in DMD patients (Hanajima &
Kawai, 1996). Atrial fibrillation possibly followed the stress related
to the procedure and to anesthesia in a DMD patient with initial
signs of cardiac involvement (sinus tachycardia 92 bpm at rest)
(Muntoni, 2003). Other rare possibilities include (i) migraine (Kurth
et al, 2012), associated with 1–14% of stroke in children (Garg &
DeMyer, 1995; Ebinger et al, 1999), (ii) minimal endothelial damage
during intra-arterial catheterism, resulting in a small thrombus that,
when detached, hours later caused the thalamic stroke; (iii): a small
amount of MABs injected in the axillary artery due to whirlpool
might have entered in the right vertebral artery, although this is
unlikely due to the relevant distance between the catheter tip (in
axillary artery) and the origin of the vertebral artery. Moreover,
post-infusion arteriography (Appendix Fig S8) never showed stop of
staining due to thrombotic events by MAB injected in high number
(hundreds of millions of cells) in the four limbs. No MRI-detectable
adverse events (inflammation, tumor formation, tissue infarction)
occurred despite the high number of cells infused. Overall, we
believe this is a relatively safe study and that the thalamic stroke
was likely related to rare but already reported cardio-embolism
consequent to atrial fibrillation (Hanajima & Kawai, 1996). Atrial
fibrillation might be generated in predisposed patients by arterial
catheterism. Minimal cardiac abnormalities should be considered as
exclusion criteria together with more stringent cardiac survey in
programming future studies.
The study provided important observations for MAB transplanta-
tion biology: DNA chimerism in muscles supplied by injected
arteries was very low, although at expected rate in calculations of
donor-to-host cells ratio; dystrophin detection was evident in the
youngest treated patient. Although the study was not designed for
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Figure 5. Effects of MAB treatment on outcome measures of DMD
patients.
A North Star scale measurement (NSAA score) plotted against age of
ambulant DMD patients before, throughout and after MAB clinical trial.
Arrows indicate time points of MAB infusion. Dotted line indicates the time
period in which Pt 05 spontaneously suspended steroids treatment without
communication to parents and clinicians. Pt 02 and Pt 05 showed score
stabilization throughout 8 months of MAB infusions; Pt 05 showed
stabilization even in the subsequent period, whereas Pt 02 showed
progressive deterioration until loss of ambulation. Pt 03 showed progressive
deterioration throughout MAB infusion and lost ambulation soon after the
end of the trial.
B 6-min walking test (meters) plotted against age of ambulant DMD patients
before, throughout and after MAB clinical trial. Arrows indicate time points
of MAB infusion. Dotted line indicates the time period in which Pt 05
spontaneously suspended steroids treatment without communication to
parents and clinicians. Pt 02 and Pt 05 showed score stabilization
throughout 8 months of MAB infusions; Pt 05 showed stabilization even in
the subsequent period, whereas Pt 02 showed progressive deterioration
until loss of ambulation. Pt 03 showed progressive deterioration throughout
MAB infusion and lost ambulation soon after the end of the trial.
C Time to run 10 m (time) plotted against age of ambulant DMD patients
before, throughout and after MAB clinical trial. Arrows indicate time points
of MAB infusion. Dotted line indicates the time period in which Pt 05
spontaneously suspended steroids treatment without communication to
parents and clinicians. Pt 02 and Pt 05 showed time stabilization
throughout 8 months of MAB infusions; Pt 05 showed stabilization even in
the subsequent period, whereas Pt 02 showed progressive increase of time
until loss of ambulation. Pt 03 showed progressive increase of time
throughout MAB infusion and lost ambulation soon after the end of the
trial.
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efficacy, we argue that we did not approach the threshold of MAB
cell dose requested for a larger cell engraftment and consequent
clinical efficacy. Older DMD patients did not change the progression
of the disease upon treatment, and only in two youngest DMD
patients we recorded clinical and biological indications of minimal
MAB efficacy. In fact, families and physiotherapists reported less
frequent falls, less rigid muscles, and a more secure ambulation in
Pt 02 and Pt 05. Moreover, functional measures remained stable in
Pt 02 during the infusion period (about 1 year), and Pt 05, at least
17 months after the first infusion. Pt 05 also showed other minimal
but significant changes as reduced deterioration of strength at the
Kin-Com ergometer and amelioration of the trend of MRI parame-
ters, which instead did not change or deteriorated in all the other
patients.
Pt 02 was the only to show unequivocal presence of donor
dystrophin detected both by antibodies directed against the deleted
domain and by a full molecular weight protein that he could not
possibly synthesize with a deletion of 40 exons. Accordingly, in
his muscles the STR chimerism analysis revealed the maximum
donor cell engraftment of 0.69%, which is consistent with a billion
MAB cells delivered to an approximately 8–10 kg mass of tissue,
and that preclinical work indicated that about 30% of donor cells
persist in the injected leg when measured after a week (Sampaolesi
et al, 2003, 2006). The origin of increased amount of dystrophin
detected in Pt 05 was clearly more complicated due to the presence
of a point mutation. To rule out the possibility that it was due to
revertant fibers, indistinguishable by Western blot, we performed
sophisticated molecular analysis that unexpectedly revealed that all
the dystrophin cDNA detected has the expected point mutation and
thus comes from the patient. However, it is not derived from spon-
taneous exon skipping, as the exon containing the mutation was
still present as the only transcript detected. We speculate that
some patients (e.g., Pt 05) may have a PTC124-like endogenous
mechanism that allows the production of some “full-length”
dystrophin, as shown for other human genes (Schueren et al,
2014). Intriguingly, Pt 05 is still walking at the time of writing.
However, given the paucity of donor MAB engraftment, a transient
paracrine effect is possible, similar to that elicited by transplanted
MSC, in a patient who likely has a slower progression of the
disease on his own.
Immunological analysis revealed that immune suppression did
not alter lymphocyte counts or their in vitro activity, and that the
only cell-mediated response to donor cells was observed in Pt 03
and was detectable before MAB infusion, suggesting that this
immunosuppressive regimen is adequate to prevent primary
responses, but is not active on memory immunological responses.
All patients had undetectable or extremely low responses against
dystrophin domains, including those absent because of large
deletions.
In conclusion, our study was relatively safe (with the exception
of a thalamic stroke) and provided relevant information essential for
planning future cell therapy protocols in DMD patients. The lack of
efficacy in treated patients as compared with preclinical work in
mice and dogs may be due to several reasons: (i) the late age of
patients at the onset of treatment and consequent advanced pathol-
ogy of their muscles—consistently, the number of regenerating fiber
was pretty low and fibrosis reduced MAB engraftment; (ii) the total
cell dose that only in the last two patients matched the one adminis-
tered to dogs; (iii) anti-inflammatory and immunosuppressive thera-
pies may have reduced MAB extravasation and thus engraftment of
the target tissue; (iv) substantial differences in the pathology
between patients and animals; (v) the fact that humans are bipeds
and need limb girdle and dorsal muscles (that we did not target)
both for posture and for motility. Further trials will target younger
patients, thus taking advantage of a less advanced pathology and a
higher cell dose in patients before the onset of symptoms. In paral-
lel, a cell-mediated gene correction strategy (e.g., artificial chromo-
somes, genome editing) that may amplify several fold the
therapeutic effect and different angiographic strategies to target
pelvic and dorsal muscles will be tested in animal models. We are
confident that the final combination of these strategies may lead to
clinical efficacy in DMD correction.
Materials and Methods
Patients and transplantation
The study was performed in compliance with Good Clinical Practice
guidelines, the provisions of the Declaration of Helsinki and the
European Directive 2001/20/EC. The San Raffaele Hospital indepen-
dent ethics committee and the Istituto Superiore di Sanita` approved
the protocol and its subsequent amendments.
We recruited 28 patients with documented (genetic and histologi-
cal) diagnosis of Duchenne muscular dystrophy, who were 6–14
years of age at the time of recruitment (March 2009), and had
healthy sibling as potential donor. All the parents agreed to their
participation in an observational study (DMD01) that we carried out
to longitudinally follow the progression of the disease for 18 months
before the onset of the interventional trial (DMD03, Eudract 2011-
000176-33, March 2011). The first study (DMD01: “Outcome
measures validation study for children affected by Duchenne
◀ Figure 6. Effects of MAB treatment on the immune response of DMD patients.A Viral and donor-specific T-cell responses were measured by IFN-c ELISpot at different time points: before the beginning of treatment (PRE), prior to each infusion,
and 2 months after the fourth infusion. Infusions are indicated by arrows. Patient’s peripheral blood mononuclear cells (PBMC) were challenged with irradiated
autologous lymphoblastoid cell lines (EBV line host), with cytomegalovirus glycine extract (CMV antigen) (Gehrz et al, 1987) and with the following irradiated cells
harvested from the donor: untreated mesoangioblasts (MAB donor), MAB activated by 48-h exposure to 500 IU/ml IFN-c (cMAB donor), myotubes differentiated from
MAB (myotubes donor) and PBMC (PBMC donor). Polyclonal stimulation (phytohemagglutinin, PHA) was used as a positive control. Donor PBMC were challenged with
autologous targets as negative controls. Results are expressed as number of specific cells/105 PBMC and calculated according to the following formula: number of
spots produced by patient’s PBMC – number of spots produced by donor’s PBMC. Results for patients Pt 01, Pt 02, Pt 03, Pt 05, and Pt 06 are shown.
B Dystrophin-specific T-cell responses were measured by IFN-c ELISpot at two time points: before the beginning of treatment (PRE, white bar) and 2 months after the
fourth infusion (black bar). PBMC were challenged with a library of 15-mer overlapping peptides covering the protein sequence (pool 1–8). Polyclonal stimulation
(phytohemagglutinin, PHA) was used as a positive control. The gray area represents the threshold calculated on a cohort of healthy donors. Results for Pt 01, Pt 02,
Pt 03, Pt 05, and Pt 06 are shown.
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Muscular Dystrophy”) was made to standardize outcome measures
as reported (Mazzone et al, 2011; Lerario et al, 2012).
Out of these 28 DMD patients, an HLA-matched sibling donor
was identified in six patients; one developed a viral myocarditis and
thus failed inclusion criteria. Eligibility criteria included, beside
indicated age, completion of clinical trial DMD01 and availability of
potential HLA identical donor MABs, the absence of concomitant
major diseases and preserved respiratory and cardiac function,
absent or modest scoliosis; parental/guardian signed informed
consent and patient’s assent.
Five patients underwent transplantation of MABs. Target dose of
MABs was consistent with doses administered to dystrophic dogs in
preclinical tests (Sampaolesi et al, 2006). Pt 01, Pt 02, and Pt 03
were infused between March and December 2011, Pt 05 and Pt 06
between November 2012 and July 2013. Intra-arterial infusion was
performed in an angiographic suite by an interventional radiologist
assisted by an anesthesiologist. Before the procedure the patient
received hydration with physiological solution 0.9% (1–2 ml/kg/h)
via catheter-port system for 12 h. Under deep sedation (propofol
4–8 mg/kg/h), analgesia (remifentanil 0.025–0.05 mcg/kg/min) and
local anesthesia (5–10 ml 1% lidocaine hydrochloride), retrograde
puncture of one common femoral artery was performed and a 4F
angiographic catheter was placed, with its tip either in the ipsilateral
or controlateral external iliac artery and, in the last two procedures
on the first three patients, also in the axillary arteries. During the
procedure, all patients were monitored (ECG, HR, NBP, SaO2). A
diagnostic angiography of the limb was performed before and after
the infusion (Appendix Fig S8). The suspension of MABs (at a
concentration of 5 × 106/ml) was infused at a rate of 1 or 2 ml/min.
To avoid cell clumping, gentle and continuous agitation of the
syringe was applied during infusion.
The first three patients (Pt 01, Pt 02, and Pt 03) received the first
two injections in the left femoral artery at an intention dose of 3.3
and 6.6 × 106 cells/kg/body weight and the last two at
19.8 × 106 cells/kg/body weight, distributed to the other three limb
arteries, so that each limb would have received a similar dose of
cells in respect to its mass. Pt 05 and Pt 06 were injected exclusively
in the femoral arteries, at an intention dose of 9.9, 9.9, 19.8, and
19.8 × 106 cells/kg/body weight. Pt 02 and Pt 05 received one and
two additional infusions at maximal dose 1 year and 6 months after
the last scheduled infusion, respectively. Only in Pt 05 and Pt 06,
the target dose was reached, and the injected doses are reported in
Appendix Table S4. Oral tacrolimus (0.05 mg/kg/dose twice daily,
target plasma level of 5–10 lg/l), weight-adjusted steroids,
acyclovir, and co-trimoxazole were administered.
Patients were weekly monitored by a local pediatrician, and at
San Raffaele Hospital every 2 months during infusions and then
every 3–5 months (for at least 3 years); they had a complete
medical examination, including blood tests, spirometry, echocardio-
graphy, electrocardiogram, cerebral and muscle MRI, and psycho-
logical evaluation. All the severe (SAE) and minor adverse events
were evaluated and classified according to National Cancer Institute
(NCI) Common Terminology Criteria for adverse events (CTCAE
v3.0, 2006), and eventual correlations with infusion of allo-MABs
were evaluated according to the Naranjo algorithm (Naranjo et al,
1981).
Outcome measures to test muscle strength, functional mobility,
endurance, and ability to walk included the 6-min walk test
(6MWT), North Star Ambulatory Assessment (NSAA), ten-meter
walk, and time to rise from floor (Gower’s sign), as well as quantita-
tive functional analysis on the Kin-Com ergometer (Mazzone et al,
2011; Lerario et al, 2012).
Medicinal product
MolMed (http://www.molmed.com) was responsible for the
production and release of MABs as medicinal product (MP). Good
Manufacturing Practices (GMP) were applied to scale up the
process of isolation, characterization, and expansion (Tonlorenzi
et al, 2007). Cells were then frozen as intermediate product (IP).
Cells were grown in MegaCell (Sigma–Aldrich) supplemented with
five ng/ml of human recombinant basic fibroblast growth factor
and 5% fetal calf serum. Features of the cells used as MP are
shown in Appendix Table S1. Cells appeared morphologically
homogenous and expressed the same phenotype (CD44 and CD13+;
CD31, CD34, and CD45) up to passage 30 at 3% O2; satellite cell-
derived myoblasts were minimally represented (<10% CD56+)
except than in one donor-derived cell population which was
depleted with anti-CD56-coated magnetic beads. The MP showed
myogenic potency as cells spontaneously differentiated into
myotubes in vitro (Appendix Fig S9). Less than 6% senescent cells
were detected (by beta-galactosidase expression) even at late
culture passages (p29). IP cells were thawed and cultured for
1 week before the infusion, and then formulated in heparinized
(5 IU/ml) normal saline solution (0.9% NaCl), constituting the
fresh MP. Suitable quality control plans for IP and cells for infusion
have been defined.
Muscle biopsies and analysis of donor cell engraftment and
dystrophin expression
Pt 01, Pt 02, and Pt 03 underwent muscle biopsy in the muscle
biceps brachii and in the tibialis anterior 2 months after the last
infusion. For Pt 01 and Pt 02, we could obtain a fragment of muscle
biopsy (quadriceps) performed at time of clinical diagnosis few
years before. Pt 05 and Pt 06 underwent muscle biopsy before the
first infusion in the vastus lateralis, and 2 months after last infusion
in vastus lateralis and gastrocnemius. All biopsies were divided in
fragments for analysis of donor DNA chimerism, histology and
immunohistochemistry, Western blot analysis, and RT–PCR and
sequencing for dystrophin expression.
Dystrophin expression was investigated by immunohistochem-
istry and Western blot with anti-dys1, dys2 and dys3 (all from
Novacastra, UK), Mandys18 (clone 5H9), and Manex46e (clone
8G10; from Wolfson Centre for Inherited Neuromuscular Disease,
UK). For three patients, quantitative immune-fluorescence analysis
was performed in double blind at ICH, University College, under the
supervision of Dr. Silvia Torelli and Prof. Francesco Muntoni as
described (Arechavala-Gomeza et al, 2010).
Regenerating fibers were identified with anti-fetal myosin anti-
body (Novocastra), counting at least 1000 fibers per patient (from
digital images of least 6 random fields acquired with 10× objective).
Light images were acquired with Olympus (BX5) microscope;
conventional fluorescence with Leica DMR microscope (Leica
Microsystem); and confocal images with Leica SP5 microscope
(Leica Microsystem).
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Donor DNA chimerism
Donor chimerism was evaluated by genomic detection of patient and
donor-specific short tandem repeats (STR) (Kristt et al, 2005).
Genomic DNA extraction was performed by QIAamp DNAmini kit,
according to the manufacturer’s recommendations (Qiagen). Chime-
rism analyses were performed by quantitative real-time PCR-based
assay (AlleleSEQR Chimerism Assay, Abbott Molecular) using AB
7500 Real-time PCR System (Life Technologies, Thermo Fisher Scien-
tific), and the donor percentages were obtained by the DDCt calcula-
tion method on triplicates for one to three informative markers.
Sanger sequencing of 6283 C>T mutation
Total RNA was extracted from muscle biopsy, and 1 lg was used in
cDNA synthesis with random hexamer primers according to stan-
dard protocols. Subsequently, Phusion polymerase (Thermo Scien-
tific) was used to amplify 544-bp product with oligos FDMD6283
(50-TGCTCCTGACCTCTGTGCTA) and RDMD6283 (50-TGACAGCTG
TTTGCAGACCT). High fidelity buffer and annealing temperature
60°C was used. PCR products were purified from agarose gel using
QIAquick gel extraction kit (Qiagen). Sequencing was carried out
using internal primers FDMD6283seq (50-CTACAACAAAGCTCA
GGTCG) and RDMD6283seq (50-CTCAGGAATTTGTGTCTTTCTG).
Donor genomic DNA was isolated from MABs using Qiagen DNeasy
Blood and Tissue Kit. Phusion polymerase with oligos FDMD6283i2
(50-GAGCGATCCACTCTCTCAGG) and RDMD6283i3 (50-GGAGGGT
AATGCAAAGTGTAAAG) was used to amplify 841-bp product
which was sequenced with internal primers FDMD6283i3 (50-CTAC
AACAAAGCTCAGGTCGGA) and RDMD6283i2 (50-ACCTCAATGCCC
CAATCTGA).
The outer primers FDMD6283 and RDMD6283 were used to
amplify PCR product with Phusion DNA polymerase, which was
sequenced to high depth with Illumina Miseq system at the Geno-
mics Core Facility of the University of Manchester. The sequence
reads were analyzed with the Integrative Genomics Viewer (version
2.3.30) (Robinson et al, 2011; Thorvaldsdottir et al, 2013). Nucleo-
tide count corresponding to either 6283C or T allele is reported.
Tetraprimer ARMS PCR was carried out according to published
protocols (Ye et al, 2001) with modifications. Primer 1 software was
used to design oligos: F(C) (50-GGGAAAAAGTTAACAAAATGTAC
AAGGCCC), R(T) (50-AACAGATCTGTCAAATCGCCCTTGGCA), F1
(50-AACTTCTCAATGCTCCTGACCTCTGTGCT), R1 (50-ATTCAATGT
TCTGACAACAGTTTGCCGC). Similar to published protocols, we
used touchdown PCR with temperature dropping 1°C per cycle from
68°C to 50°C for 18 cycles, followed by 18 cycles at 50°C. We used
Platinum Taq polymerase (Life Technologies) in tetraprimer ARMS
PCR.
Safety and tolerability
To address the risk of organ toxicity and opportunistic infections
due to combined steroid and FK506 (tacrolimus) treatment, regular
clinical, biochemical, drug-level, and virological (in particular CMV
and EBV reactivation) monitoring was instituted, at intervals
depending on patient’s condition, for the entire duration of the
immunosuppressive treatment and according to current standards of
allogeneic stem cell transplant setting. After every MAB infusion,
patients underwent blood tests to assess muscular enzymes (CK,
LDH, CK-MB, troponin T), transaminases and electrocardiography
(ECG). For 24 h after every MAB infusion, a continuous monitoring
of cardiac and respiratory parameters was performed.
Safety was also monitored by weekly clinical examination and
bimonthly by spirometry, echocardiogram, and ECG. MRI of the
lower limbs was performed before the first infusion and then every
4–6 months to assess muscular damage related to the intra-arterial
injection of MABs, to register possible ischemic events and to rule
out potential uncontrolled MAB expansion. All patients underwent a
brain MRI examination at the end of the scheduled treatments to
rule out clinically silent brain ischemic lesions.
MRI acquisition
MRI of the hips and lower limbs was performed immediately before,
after 4, 8 and 12 months from the first MAB infusion, and then
every 6 months. All MRI examinations were performed with a
3-Tesla scanner (Achieva 3T; Philips Medical Systems, Best, the
Netherlands) without sedation. For the lower limbs, the scanning
protocol consisted of axial T1-weighted spin echo (SE) sequences
(slice thickness [THK] 4 mm; repetition time [TR] 550 ms; echo
time [TE] 15 ms), axial T2-weighed turbo SE sequences (THK
4 mm; TR 7300 ms; TE 90 ms), coronal Short Tau Inversion Recov-
ery (STIR) T2-weighted sequences (THK 5 mm; TR 7100 ms; TE
70 ms; inversion time [IT] 200 ms) and coronal 3D THRIVE
T1-weighted sequences (acquired voxel size 1.25/1.25/2.50 mm,
reconstructed voxel size 1.25/1.25/1.25 mm, TR 4.2 ms, TE
2.1 ms), acquired separately on the hip, thighs and calves. During
the duration of the examination (26 min), a movie was projected.
All patients also underwent a brain MRI examination at the end
of the treatments. For the brain MRI examination, an 8-channel
phased-array dedicated coil was employed. Fluid-attenuated inver-
sion recovery (FLAIR; THK 3 mm; TR 11,000 ms; TE 120 ms; inver-
sion time [IT] 2800 ms), T2-weighted turbo SE (THK 4 mm; TR
3,000 ms; TE 85 ms), diffusion-weighted imaging (DWI; THK
3 mm; TR 5090 ms; TE 86 ms, b values 0–1,000 s/mm2), and inver-
sion recovery T1 (THK 5 mm; TR 2,000 ms; TE 10 ms; IT 500 ms)
sequences were acquired on the axial plane. Coronal and sagittal
T2-weighted turbo SE (THK 3 mm; TR 3,000 ms; TE 85 ms)
sequences were also acquired with a total scan time of 21 min,
during which a movie was projected.
MRI post-processing analysis
Signal intensity ratios (SIRs)
An experienced operator manually outlined the areas of knee exten-
sors (quadriceps), knee flexors (biceps femoris, semitendinosus and
semimembranosus), sartorius, gracilis, and gluteus maximus muscles
of both sides on axial T1-weighted images. The signal intensity from
each region of interest (ROI) was normalized to the nearby subcuta-
neous fat, thus obtaining a signal intensity ratio (SIR) to measure fat
infiltration. The SIR was measured on five slices covering the whole
length of the femur, and then, the average was calculated.
Lower limb segmental muscle volumes
On axial T1-weighted images, an experienced operator manually
segmented the thighs and legs volumes on a dedicated workstation
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(Advantage Workstation; General Electrics, Milwaukee, USA). The
anatomical landmarks for the segmentation of the volume of interest
were the inter-trochanteric line and the distal femoral metaphysis
for thigh, and the proximal and distal tibial metaphyses for leg. After
applying a signal-intensity threshold to select muscle tissue (50–160),
its volume was normalized to the previously segmented thigh and
leg volumes, to obtain thigh and leg muscle volume percentage
index (MVI).
Individual muscle volumes
The volumes of quadriceps, biceps, semitendinosus, semimembra-
nosus, sartorius, gracilis, soleus, and gastrocnemius of both limbs
were generated on axial T1-weighted images through a semi-auto-
mated system using the software Amira (FEI Visualization Sciences
Group). A signal-intensity threshold normalized to the intensity of
the subcutaneous fat in each slice was then applied to measure the
volume of the unaffected muscle tissue within the sheath. This
volume was eventually normalized to the volume of the all muscle,
obtaining percentage volumes of spared muscular tissue for each
muscle.
Statistical analyses of MRI data
To graphically describe the pattern of natural disease progression,
we considered the values of the non-treated subjects and the pre-
treatment measurements of the treated ones; we fitted a nonpara-
metric quantile regression model based on natural cubic splines as
function of time. In such model, we also included the dependencies
between data coming from the same subject. In particular, we
considered the quantiles of order s = 0.10, 0.25, 0.5, 0.75, and 0.90
to give a whole picture of the possible pattern distribution. The
quantile regression of order s = 0.5 gives the median tendency,
which was taken as main reference in the following analysis.
Onto such plots, we plotted the values from the treated subjects,
separately for leg and marked differently before–after treatment.
To further investigate the effect of treatment, for each patient we
fitted the piecewise continuous linear model y = a0  a2It0 +
(a1 + a2I)age, with a random effect on legs in order to consider the
dependencies among observations coming from the same leg, and
where t0 is the treatment day, I is a dummy variable indicating times
(age) before vs after treatment day and age is the patient’s age. In
this model, the parameter a1 gives the slope of the trend before the
treatment, and a2 gives the change of the slope after the treatment;
hence, it also gives a direct measure of the treatment effect.
Immunological studies
Peripheral blood mononuclear cells (PBMC) were isolated from
patients by Ficoll-Hypaque gradient separation (Lymphoprep; Frese-
nius). Cells were cultured overnight in IMDM (GIBCO-BRL), supple-
mented with 10% FBS. Frequencies of T cells specific for
cytomegalovirus (CMV), Epstein–Barr virus (EBV), donor PBMC,
donor MABs, and donor MAB-derived myotubes were assessed by
IFN-c ELISpot and analyzed (ElyAnalyze V4.2 Reader) as described
(Sacre et al, 2005). To further characterize alloreactive responses in
Pt 03, 100-Gy-irradiated MABs obtained from the donor were used
to stimulate patients’ PBMC in mixed lymphocyte reactions in
the presence of 60 IU/ml of rhIL2. Effectors were tested in 51Cr-
release assay for the ability to kill several donor cells. To mimic
inflammatory conditions, a fraction of MABs was exposed to IFN-c
(500 IU/ml; PeproTech) for 48 h before 51Cr labeling (Noviello et al,
2014). The frequencies of dystrophin-specific T cells were assessed
by a 36-h IFN-c ELISpot using as target, a library of overlapping
15-mer peptides covering the entire portion of dystrophin not over-
lapping with utrophin. The peptides (JPT) were divided into 8 pools,
40 peptides each, and used at a final concentration of 5 mcg/ml.
PBMC harvested from 9 healthy subjects were tested as negative
controls.
Absolute counts of circulating lymphocytes were quantified by
flow cytometry (Beckman Coulter FC500) on the CD45bright/SSClow
population with fluorochrome-conjugated monoclonal antibodies to
CD3, CD4, CD8, CD16, CD56, and CD19 and TruCount beads (Beck-
man Coulter), according to the ISCT immunological gating protocol.
Data were analyzed with FCS Express (De Novo Software). The
maturation phenotype of circulating T cells was further character-
ized by flow cytometry based on CD45RA and CD62L expression
and defined as: naı¨ve T cells (TNa, CD45RA
+/CD62L+), central
memory T cell (TCM, CD45RA
/CD62L+), effector memory T cell
(CD45RA/CD62L), and effector memory T-cell expressing
CD45RA (TEMRA, CD45RA
+/CD62L). Humoral responses to
dystrophin were evaluated by Western Blot, using proteins extracted
from human skeletal muscle. The membrane was incubated
with patient and donor sera at different dilutions and next with a
The paper explained
Problem
Muscular dystrophies are relatively common diseases that affect skele-
tal and often cardiac muscle. They vary in severity and age of onset
but all, to variable extent, progressively compromise the ability to
walk, and to move the arms, and in the most severe cases even
autonomous breathing and cardiac function. As of today, there is still
no effective treatment, although many new therapies are being tested
in patients, some with encouraging results.
Results
After many years of preclinical work in several animal models, we
conducted a “first-in-human” clinical trial in five patients affected by
Duchenne muscular dystrophy. The trial was based upon infusion in
the limb arteries of escalating doses of donor stem cells from an
immunologically related brother. Clinical, instrumental, and molecular
analyses were conducted before, during, and after the completion of
the study. The study was relatively safe: One patient developed a
thalamic stroke with no clinical consequences. However, the efficacy
was minimal, possibly due to the very low number of donor cells that
engrafted the patients’ muscles, already compromised by the
advanced stages of the disease.
Impact
This clinical study marks a milestone in the field of cell therapy even
if it was not efficacious. For the first time, it was possible to inject
hundreds of millions of non-hematopoietic stem cells in the arteries
of patients without adverse events related to the procedure itself. We
are now working on implementing the transplantation procedure, the
efficiency of genetic correction in stem cells from the same patient
aiming at applying the new protocol to younger patients, in order to
approach efficacy. Importantly, the current protocol could be applied
to and possibly increase the efficacy of the very many ongoing clinical
trials using mesenchymal stem cells that are currently injected in the
venae and are consequently trapped in the lungs.
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peroxidase-conjugated rabbit anti-human IgG (Jackson Immuno
Research). The monoclonal antibody dys1 was used as positive
control. The same dilutions were tested for recognition on influenza
virus proteins (Vaxigrip; Sanofi Pasteur), using a monoclonal anti-
body to human Influenza A (H1N1, H2N2) (Takara) as control.
Expanded view for this article is available online.
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